Cramer's Morning Take: Bristol Meyers & Eli Lilly 1/16/25

SPEAKER_1 (0:00)

At Capella University, learning the right skills could make a difference. That's why our business programs teach you relevant skills you can take from the course room to the workplace. A different future is closer than you think. With Capella University. Learn more at capella.edu. Global markets, up to the minute, front page news. Wake up to Frank Holland and worldwide exchange.

SPEAKER_2 (0:22)

Weekdays 5 a.m. Eastern CNBC.

Jim Cramer (0:24)

Live ambitiously. Jim Cramer here to share with you a sample of my take on the market from today's CNBC Investing Club morning meeting. Jeff, I had to come back and share with club members some things that I learned that are kind of off the table that people didn't get that I can help club members for because they deserve special stuff, so I came back.

Jeff (0:48)

Well, we're glad to have you back. Why don't we just jump right in to it? So you're fresh off the JP Morgan Healthcare Conference. You sat down with several clubs, CEOs, Bristol Meyers, Lilly, Abbott Labs. Yes.

Jim Cramer (0:59)

Now Bristol Meyers, dramatically undervalued, happened to come and talk with me the same day that J&J bought a company that, by the way, does not have the solution to schizophrenia from 2019 I don't understand the J&J acquisition, but it certainly didn't hurt Bristol Meyers. I would buy that aggressively. The numbers that they get and where they're going with bipolar, where they're going with Alzheimer's is going to make it so that may be the best stock we own for 2026

Jeff (1:32)

So the ad interview was Monday. You can check it out online if you haven't seen it. So I guess if it's not mentioned today, we could buy it tomorrow, restricted to today.

Jim Cramer (1:40)

We have to. The numbers that they're getting are, there are no side effects. This drug will be used by even, I was speaking with the mayor of San Francisco. It will be the antidote to homelessness because he said it'll use percent of those people as schizophrenic.

Jeff (1:57)

Yeah, and then Lilly, you sat down with Rick maybe five, 10 minutes after they gave their prelim Q4 numbers, which were soft, but the 25 guidance was good.

Jim Cramer (2:06)

Yeah, he basically told me, and I saw him later on, he said, look, this quarter unimportant. They had issues with distribution. He wasn't happy with his own, obviously, his ship rate. But by the way, the main issue is dispersion. Are people quitting it? And he directly disputes everybody who says, they do it for one year. He does believe that co-mobility is going to be very important about who's going to get it and who's not. He's not the least bit concerned about the idea that diet and exercise is the regime that Bobby Kennedy wants. He said, look, it'll save the system. Obviously, there's pros and cons. But he was so bullish that it was kind of difficult to restrain him. So therefore, it's difficult for me to restrain me. I think it goes much harder.

Jeff (2:59)

Yeah, after two straight misses, but they're getting more indications, right? Sleep apnea was one, maybe a pill next year. Another one we said.

Jim Cramer (3:07)

They can't meet the man. There's a problem in the system that these middlemen don't help. But he said, look, we haven't gone to China. We haven't gone to India. We haven't gone worldwide. We're an anyone. And the results are sensational for so many different diseases. He's far more bullish than anyone. And doesn't he know the data?

Join the CNBC Investing Club with Jim Cramer to catch my member-exclusive morning minis every day at 10, 20 a.m. Visit cnbc.com/morningtake to become a member today. That's one word, morning take.

SPEAKER_2 (3:50)

All opinions expressed by Jim Cramer on this podcast and in connection with the CNBC Investing Club are solely Cramer's opinions and do not reflect the opinions of CNBC, NBC Universal or their parent company or affiliates and may have been previously disseminated by Cramer on television, radio, internet or another medium. No specific outcome or profit is guaranteed in connection with your reliance upon or other use of the content from Cramer. The opinions offered in connection with this podcast and the CNBC Investing Club are not an attempt to induce any particular trading behavior, investment or strategy. You should be aware of the risk of loss in following any strategy or investment discussed in the content from Cramer. To view the full CNBC Investing Club Disclaimer, please visit cnbc.com/investingclubdisclaimer.

SPEAKER_1 (4:34)

At Capella University, learning the right skills could make a difference. That's why our business programs teach you relevant skills you can take from the course room to the workplace. A different future is closer than you think. With Capella University. Learn more at capella.edu.